

INVITATION

Alemtuzumab:

Exploring a New
Treatment Approach for

MS

SATELLITE SYMPOSIUM

Friday, 11 September, 2009
19:15 – 20:15

Congress Center Düsseldorf
Main Auditorium



Bayer HealthCare
Bayer Schering Pharma

genzyme

Satellite Symposium of the ECTRIMS 2009 Congress

W E L C O M E

Dear Colleagues,

It is my great pleasure to invite you to the satellite symposium entitled "Alemtuzumab: Exploring a New Treatment Approach for MS". Alemtuzumab, a humanized monoclonal antibody targeting CD52 on circulating lymphocytes, is currently in Phase 3 clinical development as a potential therapy for patients with relapsing remitting multiple sclerosis (RRMS).

The first speaker will be Dr. Alasdair Coles, a lead investigator in the pilot and Phase 2 studies of alemtuzumab in MS. Dr. Coles will review key findings from these studies including data published in the *New England Journal of Medicine*. These results detail an evaluation of the safety and efficacy of alemtuzumab versus interferon beta-1a in a 3 year clinical trial in patients with RRMS.

Dr. Bruce Roberts will then present what has been learned about alemtuzumab's effects from studies in transgenic mice. Finally, Dr. Eva Havrdova will review the clinical development program including the newly launched extension study, designed to further characterize the long term safety and efficacy of alemtuzumab in MS.

I look forward to welcoming you to what promises to be a stimulating and exciting symposium dedicated to researching this investigational treatment for people with MS.



Professor Hans-Peter Hartung, Meeting Chair
*Chairman, Department of Neurology
Heinrich-Heine-University
Düsseldorf, Germany*

Alemtuzumab is not approved for treatment of MS and should not be used in MS patients outside of a regulated clinical trial.

To learn more, please visit
Genzyme Medical Affairs at booth #302

Please join us for the Alemtuzumab satellite symposium on Friday, 11 September 2009. We look forward to your attendance and participation during this symposium, which promises to be an informative exchange of views and experiences.

To confirm your attendance, kindly register online at:

www.regonline.com/ECTRIMS

A G E N D A

19:15

Welcome

Professor Hans-Peter Hartung (Germany)

19:20

Clinical Experience

Dr. Alasdair Coles (United Kingdom)

19:40

Mechanistic Insights from the Human CD52 Transgenic Mouse

Dr. Bruce Roberts (United States)

19:55

Investigating Long Term Safety and Efficacy

Dr. Eva Havrdova (Czech Republic)

20:05

Questions and Panel Discussion

*Moderator: Professor Hans-Peter Hartung
Professor Alastair Compston, Dr. Alasdair Coles,
Dr. Bruce Roberts, Dr. Eva Havrdova*